Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured a major regulatory milestone in the US, with the Food and Drug Administration granting a CLIA waiver for its flagship FebriDx point-of-care test, significantly expanding its commercial reach across primary and outpatient care settings.
The approval follows 510(k) clearance and enables FebriDx to be used in a far broader range of healthcare environments, triggering US$5.5 million in milestone payments and opening access to a substantially larger patient population and addressable market.
CLIA waiver expands access and market reach
The CLIA waiver allows FebriDx to be used in more than 300,000 healthcare locations across the US, including primary care clinics, urgent care centres, retail pharmacies and community health settings that hold a Certificate of Waiver.
This marks a step-change from its previous classification, which limited use to moderate-complexity laboratory settings such as hospitals.
With the expanded access, Lumos estimates FebriDx could now be deployed to address around 80 million patient presentations annually in the US, representing a total market opportunity exceeding US$1 billion — roughly 15 times larger than previously available.
The test delivers results within 10 minutes and is designed to differentiate between bacterial and non-bacterial respiratory infections, supporting faster clinical decision-making and more targeted use of antibiotics.
CEO Doug Ward described the approval as a “transformative moment” for the company and for the management of acute respiratory infections in the US.
“This approval opens access to a vastly larger market — allowing healthcare professionals in outpatient clinics to deliver rapid and accurate results at the time of the consultation to deliver more effective patient outcomes,” he said.
Milestone payments and commercial rollout support
The regulatory milestone triggers immediate and near-term payments under Lumos’ existing commercial and government partnerships.
Under its exclusive US distribution agreement with Phase Scientific — valued at up to US$317 million — the CLIA waiver activates a US$5 million payment. A further US$507,377 milestone payment will be received under Lumos’ contract with the Biomedical Advanced Research and Development Authority (BARDA).
These funds are expected to strengthen the company’s balance sheet and support the ongoing US commercial rollout of FebriDx.
Lumos said its broader commercial strategy will focus on driving adoption through healthcare provider education, integration into outpatient workflows and continued progress on reimbursement with private payors. Partnerships with Phase Scientific, PRO-spectus and AcuityMD are expected to support this rollout.
Ward noted that the latest milestone “also highlights the invaluable support of our partner, BARDA, whose continued collaboration underscores the importance of public-private collaboration in combating antimicrobial resistance and enhancing patient care”.
Fresh capital backs US expansion
The company’s progress is now being backed by fresh capital, with Lumos also announcing on Friday a strongly supported A$20 million institutional placement alongside a share purchase plan, with proceeds earmarked to accelerate US commercialisation of FebriDx, expand manufacturing capacity and support sales and marketing efforts.
The updates build on recent momentum for Lumos and FebriDx in the US market, including progress on reimbursement pathways, growing sales and a paediatric study supported by BARDA.
That paediatric study, if successful, could extend the use of FebriDx to children aged between two and 12 years, further broadening the test’s clinical utility and market reach.
More broadly, the CLIA waiver positions Lumos to scale FebriDx into routine frontline healthcare settings, where rapid diagnostics can play a growing role in managing respiratory infections and addressing antimicrobial resistance — a key focus for US health authorities.